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Abstract Autism spectrum disorder is a genetically com-
plex and clinically heterogeneous neurodevelopmental
disorder. A recent study by the Autism Genome Project
(AGP) used 1M single-nucleotide polymorphism arrays to
show that rare genic copy number variants (CNVs),
possibly acting in tandem, play a significant role in the
genetic aetiology of this condition. In this study, we
describe the phenotypic and genomic characterisation of a
multiplex autism family from the AGP study that was
found to harbour a duplication of exons 31–44 of the
Duchenne/Becker muscular dystrophy gene DMD and also
a rare deletion involving exons 1–9o fTRPM3. Further
characterisation of these extremely rare CNVs was carried
out using quantitative PCR, fluorescent in situ hybridisation,
long-range PCR amplification and sequencing of junction
fragments. The maternal chrX:32,097,213-32,321,945 tan-
dem duplication and paternal chr9:72,480,413-73,064,196
deletion(NCBIbuild36coordinates)weretransmittedtoboth
affected boys, potentially signifying a multi-hit mechanism.
The DMD reading frame rule predicts a Becker phenotype,
characterised by later onset and milder symptoms. When last
evaluated, neither child had developed signs of muscular
dystrophy. These data are consistent with a degree of
comorbidity between autism and muscular dystrophy and
suggest that genomic background as well as the position of
the mutation within the DMD gene may impact on the
neurological correlates of Duchenne/Becker muscular dys-
trophy. Finally, communicating unexpected findings such as
these back to families raises a number of ethical questions,
which are discussed.
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Introduction
Autism is a highly heritable and heterogeneous neuro-
developmental condition affecting approximately 0.2% of
the general population (Fombonne 2009). Whilst a number
of rare, highly penetrant genetic variants have been
reported, a large proportion of the condition’s heritability
remains unaccounted for (Abrahams and Geschwind 2008).
A recent high-resolution genome scan carried out by the
Autism Genome Project consortium (AGP) comprising
almost 1,000 individuals with autism spectrum disorder
(ASD) suggests that rare genic copy number variants
(CNVs) play a significant role in the aetiology of this
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DOI 10.1007/s11689-011-9076-5condition (Pinto et al. 2010). Interestingly, more than 0.6%
of affected individuals had two or more de novo CNVs
(Pinto et al. 2010), a figure consistent with an earlier single-
nucleotide polymorphism (SNP) array study comprising
427 ASD cases (Marshall et al. 2008). Another recent study
detected an increased frequency of “second-hit” CNVs in
individuals with developmental delay and deletion of
16p12.1 (Girirajan et al. 2009). A third study found two
rare CNVs involving CNTNAP5 and DOCK4 (inherited
from the father and mother, respectively), each transmitted
to both members of an autistic sibling pair (Pagnamenta et
al. 2010). These studies highlight the emerging evidence for
multiple rare genomic variants combining in the same
individual resulting in a particular phenotype (Cook and
Scherer 2008).
Recent studies show that the incidence of autistic traits in
both Duchenne (DMD) and Becker muscular dystrophy
(BMD) cohorts is higher than observed in the general
population. In the largest study, 11 of 351 (3.1%) boys with
DMD were reported to have ASD, according to parental
questionnaires (Hendriksen and Vles 2008). In another study,
direct screening of 85 boys with DMD or BMD revealed 16
(19%) meeting the criteria for ASD (Hinton et al. 2009). In a
smaller study focussing on the milder BMD phenotype, 2 of
24 (8.3%) were described as having autism (Young et al.
2008). About 20% of patients with DMD have intellectual
disability, whereas the frequency is lower (∼10%) in those
with BMD (Young et al. 2008;E m e r ya n dM u n t o n i2003).
Data suggest that the location of the mutation within the
dystrophin gene (DMD) may impact on the risk of cognitive
impairment. One such analysis showed that for individuals
with mutations in exons 46–79, the IQ was an average of 17
points lower compared to individuals with mutations
proximal to exon 45 (Taylor et al. 2010). Thus, mutations
at the 3′ end of DMD, which disrupt all dystrophin products,
including the shorter brain-expressed isoforms Dp140 and
Dp71, are more likely to result in cognitive impairment
(Taylor et al. 2010; Daoud et al. 2009). To better determine
the nature of this comorbidity and understand why only a
proportion of cases have social and/or cognitive impair-
ments, it is important to describe additional autism/learning
disability pedigrees harbouring DMD mutations and provide
full details not only of the DMD genotype and phenotype but
also of the genomic background and potential environmental
risk factors. The difficulty of establishing a true increase in
the risk for neurological outcomes when studying a group of
children with identifying developmental syndromes is also
worth noting, given the inherent challenges in blinding and
the use of standardised diagnostic instruments which still
contain some variability in their use between sites and
assessors.
A recent genome-wide scan CNVs carried out by the
AGP (Pinto et al. 2010) found that three individuals from
996 ASD families harboured exonic CNVs in DMD
compared to a general population incidence of DMD and
BMD in males of 1 in 3,800 and 1 in 18,000, respectively
(Mostacciuolo et al. 1987). In addition to an ∼225-kb
duplication within DMD, one of these individuals and his
affected brother carried a second rare deletion of ∼580 kb
on chromosome 9q21, potentially contributing to their
autism phenotype. In this study, this family is described in
more detail, with a combination of molecular methods
being used to characterise both of these CNVs at base pair
resolution.
Materials and methods
Family details
The family is from the IMGSAC cohort described
previously (IMGSAC 2001) and consists of father
(3019.1), mother (3019.2), two affected brothers (3019.3
and 3019.5) and an unaffected sister (3019.4). Both affected
individuals were classified with narrowly defined autism
using the Autism Diagnostic Interview-Revised and Autism
Diagnostic Observation Schedule (ADOS) instruments
(Rutter et al. 2003; Lord et al. 2001). Karyotype and
FMR1 testing gave negative results. Genomic DNA
obtained from blood was available for all members of the
pedigree. The family provided informed consent and the
study approved by the Oxfordshire Psychiatric Research
Ethics Committee A and locally by the Institute of
Psychiatry Ethical Research Committee.
Clinical details for 3019.3 (proband)
Participant 3019.3 was born by spontaneous vaginal
delivery after a normal pregnancy, weighing 3,140 g and
with head circumference in the 10–25 centile. No abnor-
malities were seen at birth and he had an Apgar score of 9.
Language development was delayed, with first words at
30 months and short phrases at 42 months. He sat unaided
at 9 months, walked at 13 months and achieved toilet
training after age 4.5. However, his medical notes show that
there was a developmental disorder of language, with a
diagnosis of articulation dyspraxia. He was noted to be
clumsy and have poor coordination (although his handwrit-
ing appears to be fine), with odd head movements and
frequently getting his body into strange contortions. A
school report (age 5.5) noted that the proband’s gross motor
control was very poor and that his legs did not bend. His
walking and running abilities were akin to those of a much
younger child.
Obsessional interests were noted from age 2, and he did
not play normally with toys or with other children. At
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areas except articulation. He was an active child liking a lot
of stimulation, but was afraid of crowds, preferring to
remain indoors with his mother, and had temper tantrums
daily. Autistic features were described as being clearest
until the age of 4; however, he still met criteria for autism
when assessed with the ADOS, aged 20 years and
10 months. His verbal and performance IQ, measured with
the Wechsler Preschool and Primary Scale of Intelligence at
age 5 years and 8 months, was 87 and 76, respectively.
However, his verbal IQ was measured again using the
British Picture Vocabulary Scale (BPVS) at age 22 years
and 7 months and was 130.
Clinical details for 3019.5
Participant 3019.5 (younger brother of 3019.3) was born by
spontaneous vaginal delivery after a normal pregnancy,
weighing 3,380 g and with head circumference in the 10–
25 centile. No abnormalities were seen at birth. First words
were at 12 months, with first phrases delayed at 60 months.
He sat unaided at 8 months and walked at 17 months; toilet
training was not fully achieved at age 8 when he was seen
for diagnostic assessment. Clinical notes describe a general
developmental delay, and as an adult, he has moderate
learning difficulties. His verbal IQ was measured using the
BPVS aged 11 years and 2 months and was 62. Our
existing medical notes do not indicate any specific prob-
lems with his motor development.
Quantitative PCR
Quantitative PCR (qPCR) experiments were performed
using iQ™ SYBR® Green Supermix (BioRad) following
the manufacturer’s protocol. qPCR primers were designed
using Primer3 (Electronic supplementary material (ESM)
Table 1 and Fig. 1a). Thermocycling conditions are given in
the Electronic supplementary material. Relative copy
number was determined using the 2
-ΔΔCt method (Pfaffl
2001).
Long-range PCR and sequencing of junction fragments
Long-range PCR was performed for the DMD and TRPM3
CNVs using the BIO-X-ACT long DNA polymerase
(Bioline) and the SequalPrepTm Long PCR kits (Invitro-
gen), respectively. Reactions were performed according to
the manufacturers’ instructions, with thermocycling con-
ditions listed in the Electronic supplementary material.
Primers for the DMD duplication used combinations of
qPCR primers. Those for TRPM3 were designed using
Primer3 (ESM Table 1 and Fig. 1). PCR products were
purified using Exonuclease I (NEB, Ipswich, MA) and
shrimp alkaline phosphatase (USB, Cleveland, OH). Sanger
sequencing was by BigDye v3.1 chemistry (Applied
Biosystems, Foster City, CA).
Sequencing TRPM3 and microRNA MIR204
Primer sequences (ESM Table 2) and PCR conditions are
listed in the Electronic supplementary material.P C R
purification and sequencing were performed as described
above.
Fluorescence in situ hybridisation
Fluorescence in situ hybridisation (FISH) was performed on
chromosomes obtained from EBV-transformed B-
lymphoblastoid cell lines. For the DMD duplication, a
BAC (RP11-168F15) and a fosmid (G248P86682a6) that
map within the CNV were chosen as probes (ESM Fig. 1a).
For the TRPM3 deletion, two BAC clones were used:
RP11-89K20 within the CNV and RP11-240L5 outside it
(ESM Fig. 1b). More details are available in the Electronic
supplementary material.
Results
Exonic CNVs in DMD from a recent AGP study
In a recent genome-wide scan for CNVs performed by the
AGP using Illumina 1M SNP arrays, three male probands
from 996 ASD families harboured exonic CNVs involving
DMD (Pinto et al. 2010). In one male proband, a 29.4-kb
deletion removed exon 48 of DMD. This leaves the reading
frame intact, but is predicted to remove 62 amino acids.
This variant would thus be expected to have a relatively
minor effect on the structure of the 3,685 residue protein
and was not detected in the affected brother. In another
affected boy from a multiplex family, a 381.6-kb duplica-
tion affected the 5′ end of the gene, including the start
codon of the full-length isoform. It is difficult to predict
what effect this mutation might have on DMD dosage or
protein structure and no DNA was available from the
affected brother to test segregation. Here, we focus on the
third family (3019), which harbours an ∼225-kb duplication
involving the central portion of the gene and for which
DNA was available from the affected brother for further
testing.
Fine-mapping and segregation of DMD duplication
in family 3019
In this third family, a maternally inherited duplication of
Xp21.1 was detected in subject 3019.3 during a large
126 J Neurodevelop Disord (2011) 3:124–131genome-wide scan for CNVs (Pinto et al. 2010). After
manual inspection of the log R ratios and B allele
frequencies in BeadStudio, the maximal and minimal
duplicated region was determined to be from rs16990134
to rs5972556 and from rs1795588 to rs1555256, respec-
tively (ESM Fig. 1a). At the proximal end, this resolution
was not sufficient to determine which combination of exons
had been duplicated. Therefore, qPCR was used to validate
and resolve the mutation further. These data showed that
the duplication involved exons 31–44 (Fig. 1a) and so is
predicted to leave the reading frame intact. These qPCR
results also indicated that the affected brother (3019.5) had
inherited the same mutation from the mother, whilst the
unaffected sister did not carry this variant (Fig. 1a).
A rare CNV disrupting TRPM3 in the same family
Previous studies suggest that mutations at the 3′ end of DMD,
disrupting the shorter brain-expressed isoforms (Dp140 and
Dp71), are more likely to result in cognitive impairment
(Taylor et al. 2010). As the mutation in family 3019 involved
the middle section of the gene, we considered other potential
contributory factors for the neurological phenotype. We
therefore examined the genomic background, looking for
other rare CNVs (present at <1% frequency and >500 kb in
size) in this family, and identified a partial deletion of TRPM3
on chromosome 9q21, from Illumina 1M data (Pinto et al.
2010). SNP array data showed that this CNV was present in
the proband (3019.3) and inherited paternally. Manual
inspection of the genotyping data determined the maximal
and minimal duplicated region to be from rs1011308 to
rs10781006 and from rs1317604 to rs17056622, respectively
(ESM Fig. 1b).
The CNV was validated experimentally by long-range
PCR using primers designed to flank the predicted break-
points (ESM Table 1 and Fig. 1b). This confirmed the
presence of the CNV in both the father and proband, as well
as both siblings (Fig. 1b).
The segregation pattern seen for both rare CNVs in this
family (Fig. 1c) was consistent with haplotype flow
determined from data generated in a previous linkage study
(Szatmari et al. 2007) and could suggest a multiple-hit
mechanism whereby both rearrangements contribute to the
autism phenotype.
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Fig. 1 Segregation of two rare CNVs in family 3019. a qPCR results
for fine mapping distal and proximal ends of the DMD duplication.
Results are normalised to a qPCR assay from outside the duplicated
region and then compared to the father for whom the 1M SNP array
indicated did not have the duplication. ASS alternative start site. b
Agarose gel showing long-range PCR products. Presence of the
TRPM3 deletion is indicated by an ∼8-kb fragment. c Pedigree
summarising CNV status. Shaded symbols correspond to autism. Blue
and red fonts indicate most likely maternal TRPM3 haplotype flow, as
determined using Merlin analysis of 10K SNP data. Birth order has
been switched to ensure family anonymity
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Haplotype flow also indicated that the non-deleted (mater-
nal) version of TRPM3 and the microRNA MIR204 was
shared identical-by-descent in the two affected sons
(Fig. 1c), and so we considered whether the deletion might
be unmasking a rare point mutation in trans. However,
Sanger sequencing of all 25 TRPM3 exons and intron/exon
boundaries uncovered only one non-synonymous variant
(rs6560142) on this shared chromosome, situated near the
3′-untranslated region and reported to have an average
heterozygosity of 0.449 ± 0.152. There were also no rare
variants found in MIR204.
Further characterisation of both CNVs
Although the SNP array and qPCR confirmed that exons
31–44 of DMD were duplicated, they could not distinguish
whether the extra segment of DNA was situated in tandem
with the normal copy or at a different genomic locus. Fibre
FISH using BAC and fosmid probes confirmed that the
duplication was in a direct tandem repeat orientation
(Fig. 2a) and therefore that the functional copy of DMD
was disrupted.
In order to validate the TRPM3 deletion by an
independent method, additional interphase and metaphase
FISH was performed for the proband, with chromosome
spreads from the mother used as an undeleted control.
These results confirmed the presence of the 9q21 deletion
in the proband (Fig. 2b).
Finally, to determine whether these two rare CNVs may
have been mediated by repetitive elements, we mapped the
breakpoints at base pair resolution by sequencing the long-
range PCR amplicons. For the DMD duplication, the
sequencing electropherogram further confirmed that the
tandem duplication was in a direct orientation and resolved
the genomic location as chrX:32,097,213-32,321,945,
inclusive (NCBI build 36; Fig. 2a, c), with a size of
224,733 bp. Sequencing the TRPM3 junction fragment
amplicon using an internal sequencing primer determined
44            44           
B 
← intron 30         ← intron 44 
A 
C 
exons 1-12 
31   31
Fig. 2 Further molecular characterisation of both rare CNVs. a Fibre
FISH images from normal X chromosome from mother (upper) and
duplicated X chromosome from proband (lower). Schematic shows
DMD duplicons alongside position of primers used for long-range
PCR. b Interphase and metaphase FISH images from proband for the
TRPM3 locus. The deleted chromosome 9 is missing the signal from
the RP11-89K20 probe (green). c Electropherograms with breakpoint-
spanning sequences across the DMD duplication (upper) and TRPM3
deletion (lower)
128 J Neurodevelop Disord (2011) 3:124–131the deleted bases to be chr9:72,480,413-73,064,196
(Fig. 2c) and therefore 583,784 bp in size. The deletion
thus removes the 5′ end of TRPM3 spanning the first nine
exons of the gene and the microRNA MIR204. There was
no obvious homology at each end of either rearrangement,
ruling out non-allelic homologous recombination and other
homology-based CNV mechanisms.
Discussion
In a recent genome-wide scan for CNVs, three male
probands from 996 ASD families harboured exonic CNVs
involving DMD, all being detected by multiple CNV
calling algorithms and inherited maternally. In contrast, a
single exonic CNV involving DMD was detected in one
female subject out of the 1,287 controls assessed (Pinto et
al. 2010). These data are consistent with a degree of
comorbidity between DMD/BMD and ASD, as described
previously (Hendriksen and Vles 2008; Young et al. 2008).
In this study, a combination of molecular methods has been
used to characterise two rare CNVs within one of these
families. The first CNV was a 225-kb duplication in the
DMD gene, found in the two individuals with autism and
their mother. It has previously been reported that DMD
duplications sometimes lead to unexpected splicing patterns
(White et al. 2006), and so we cannot be sure that the exon
44 donor splice site is compatible with the exon 31 splice
acceptor. The reading frame rule should thus be applied
with caution. As this patient was diagnosed with autism and
had not manifested any obvious signs of muscular
dystrophy at the time of inclusion in the study, no muscle
biopsy material is available to test what effect the mutation
has on the dystrophin protein. Nevertheless, the duplication
observed leaves the reading frame intact and is predicted to
result in an additional 735 amino acids in the middle of the
dystrophin protein. The production of an elongated but
partially functional form of dystrophin is predicted to result
in a Becker phenotype. If the variant had a more severe
impact on DMD, the patients would likely have presented
with muscular dystrophy when evaluated as young adults.
Interestingly, a similar duplication involving exons 31–44
has been previously identified in an individual with BMD,
referred for molecular testing aged 14 years (Stockley et al.
2006); Stockley, January 2010, personal communication),
consistent with our interpretation.
The second CNV identified in the family deleted the 5′
portion of TRPM3 (transient receptor potential melastatin
3). This variant was paternally inherited by all three
children and is particularly rare, being found in only this
one family in the AGP study of 996 ASD families and in
none of the 1287 control samples (Pinto et al. 2010). In
addition, there are no similar multi-exonic CNVs listed in
the Database of Genomic Variants (Iafrate et al. 2004),
March 2010 freeze. Although to date no clear link has been
established between this gene and ASD susceptibility, it is
an intriguing candidate, representing a potential second hit
contributing to the autism phenotype in this family. TRPM3
encodes a calcium permeable ion channel (Naylor et al.
2010) and is expressed in the brain. Of the seven other
paralogous members of the TRPM subfamily, TRPM3 is
most closely related to TRPM1, a gene localised within the
ASD-associated 15q13.3 deletion, providing further evi-
dence for a potential role in susceptibility in this family.
TRPM3 is localised to neurons prior to myelinisation and to
oligodendrocytes during differentiation (Hoffmann et al.
2010). The gene has multiple splice forms with different
functional properties, although how this affects their
physiological role is unclear (Nilius & Voets 2008). The
neurosteroid pregnenolone sulphate is known to improve
synaptic function, neuroprotection, myelinisation and hip-
pocampal neurogenesis. TRPM3 is directly activated by this
steroid and, as the gene is expressed in the brain, provides a
possible mechanism by which pregnenolone mediates its
effects. However, it has yet to be shown that pregnenolone
has such an effect on TRPM3 under physiological con-
ditions (Nilius and Voets 2008). A deletion involving
TRPM3 has previously been found in a patient with Kabuki
syndrome, a rare, clinically recognisable congenital mental
retardation syndrome (Kuniba et al. 2009). However, the
relevance of this finding is not clear, given that a recent
study identified mutations in the MLL2 gene in over 60% of
patients with Kabuki syndrome (Ng et al. 2010).
The segregation pattern and rarity, together with back-
ground literature on the genes disrupted, have led us to
hypothesise that these genomic variants might act as two
separate “hits” influencing autism risk in this multiplex
ASD pedigree. However, it must be noted that the majority
of pedigrees are also likely to harbour multiple rare or even
private CNVs. As the numbers of subjects undergoing high-
resolution genome-wide CNV analysis increases, the roles
of these two genes in ASD susceptibility will become
clearer. Future studies should formally assess whether
individuals with ASD and DMD mutations are more likely
to have a second hit, in TRPM3 or other brain-expressed
genes, compared to individuals with DMD mutations but no
autism.
By using the high-resolution 1M SNP data to design
nine qPCR arrays and then reusing two combinations of
these same primers for long-range PCR amplification of
junction fragment, base pair resolution of the duplicated
sequence was obtained in under 4 weeks. For the TRPM3
deletion, SNP array data were sufficient to render the
intermediate qPCR step unnecessary. These data demon-
strate the ease with which CNV breakpoints can now be
mapped. The latest developments in next-generation se-
J Neurodevelop Disord (2011) 3:124–131 129quencing are now starting to mean that CNV discovery and
identification of breakpoints happen simultaneously.
The increasing resolution and availability of genome-wide
microarrays means that the likelihood of unexpected genetic
diagnoses isescalating.For example,a recentarrayCGHscan
studying the genetics of learning disability identified a de
novo deletion of 17p13.1 involving the gene encoding the
tumour suppressor P53 (Schwarzbraun et al. 2009). This
unanticipated genetic diagnosis of Li–Fraumeni syndrome
led to increased cancer surveillance in this subject. The two
individuals described in our case report also raise similar
ethical issues about unexpected findings arising from
research studies. Information provided during the IMGSAC
consent procedure states that “if any significant abnormality
is found on either physical examination or laboratory testing,
we would inform you and your GP of the results, their
potential significance and advise on any further investiga-
tions that may be required”. We considered this duplication
of DMD to be an “abnormal” finding of potential clinical
relevance, worth reporting to the family. Although BMD is
currently incurable, confirmation by a diagnostic laboratory
and further clinical assessment could lead to better manage-
ment of the condition in these two individuals, the potential
for genetic counselling and increased surveillance for heart
conditions which are associated with BMD. A recent study
of 30 individuals with BMD and dilated cardiomyopathy
suggests that measurement of the variations in beat-to-beat
intervals can act as a further predictor of cases at risk of
sudden death and so may help suggest which BMD patients
may benefit most from treatment with ACE inhibitors or, in
the future, implantable defibrillators (Ammendola et al.
2006). For family 3019, it is worth noting that a distant
maternal cousin (male) was described as having died
suddenly of an unknown cause.
Before recommending that these two individuals be
tested for creatine kinase levels, we decided to first
characterise this duplication in more detail. Whilst qPCR
was used to determine the exact combination of exons that
were involved, other molecular methods were used in order
to confirm that the duplication was in tandem and thus
disrupting the functional copy of DMD. These additional
experiments thus allowed a more complete picture of the
genomic disruption to be communicated to the relevant
clinicians.
There has been much recent discussion about whether
research findings such as these should be communicated
to participants on an individual basis (Miller et al. 2010).
Even in the context of fully accredited clinical genetics
testing, a recent study has shown that relatives of patients
often prefer to postpone testing, depending on their
personal circumstances (Dancyger et al. 2010). For
families which are part of large research cohorts and for
whom consent was taken a long time ago (∼14 years in the
case of family 3019), this issue is particularly difficult.
Subjects will likely have forgotten the information
provided at the time of consent and so any genetic
information communicated to them may come as a
surprise, especially if it confers risk for a condition other
than that for which the individual came to clinical
attention. In cases like this, we believe that the family’s
doctor is best placed to make a decision on how best to
inform the parents. However, our experience with family
3019 also highlights another issue associated with the
passage of time—our records were out of date and so it
was initially difficult to trace the family’sd o c t o r .
In conclusion, we describe the phenotypic and molecular
characterisation of a multiplex autism family found to have
two rare CNVs disrupting the DMD and TRPM3 genes.
Although various studies propose a link between the
location of the mutation within the DMD gene and
cognitive ability, there are insufficient data to carry out a
similar analysis specifically for DMD and ASD. As well as
raising important issues about the communication of
research findings, the family described in more detail here,
taken in the context of other studies proposing two-hit CNV
mechanisms (Girirajan et al. 2009; Pagnamenta et al. 2010;
also AGP family 5126 in which a IL1RAPL1 duplication is
found in cis with the DMD variant; Pinto et al. 2010),
suggests that genomic background may also play an
important role in modulating neurological outcomes in
individuals with DMD mutations.
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